Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F520 with Nab-paclitaxel and Bevacizumab in Second-line CUP
NCT04848597Phase 2Unknown
- Sponsor
- Fudan University
- Start
- May 2021
- Primary completion
- May 2023
- Countries
- 1
01
Overview
A Phase 2 trial of rulonilimab in cancer of unknown primary (CUP), sponsored by Fudan University. Status: unknown.
02
Drugs
rulonilimab
03
Conditions
cancer of unknown primary (CUP)
Beyond the preview
Go deeper on NCT04848597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04848597.